ResearchersLinks

Short Communication · Volume 52, Issue 4, 22 April 2020 · Open Access

In Silico Profiling of Regulatory MicroRNA Targets in Programmed Cell Death 1 Gene

· · · · · · · · · · ·

Affiliations & Notes ⌄
  1. 1Department of Clinical Medicine and Surgery, Faculty of Veterinary Science, University of Agriculture, Faisalabad, Pakistan 2Department of Physics, University of Gujrat, Gujrat, Pakistan 3Department of Biochemistry, Faculty of Medicine, University of Lorraine, Nancy, France 4Department of Preventive Veterinary Medicine, College of Animal Science and Technology, Huazhong Agricultural University, Wuhan 430070, Hubei, China 5Department of Basic Sciences (Pharmacology), Khan Bahadar Choudhry Mushtaq
Article Info ⌄
Journal:
Pakistan Journal of Zoology
Published:
22 April 2020

From the article

  • If validated by experiments, these miRNAs might be used as novel biomarkers for regulation of PDCD1 gene.
  • Keeping in view of importance of computer based prediction databases miRDB has been used in our study to mine the miRNAs targeting PDCD1 gene in human beings.
  • We have identified 26 specific miRNAs in humans which can target different regions in PDCD1 gene.
  • Our data will provide concrete bases for the validation of these miRNAs in silencing of PDCD1 gene.

Selected from the article's own text.

Abstract

MicroRNAs (miRNA) are the novel class of small non-coding RNAs comprising of 17-24 nucleotides that, targets in silencing of one or more genes. Despite their importance as gene regulator, computational strategies are still at its initial stages. Several computer based prediction databases remain the only foundation for rapid identification of putative microRNA target. By utilizing experimentally validated targets, the search of further targets via bioinformatics tools help to predict gene target site. Keeping this in view, a study has been planned to investigate PDCD1 gene regulatory miRNA targets, their sequences and their seed location in human using online server miRDB. We have identified 26 specific miRNAs (hsa-miR-939-3p, hsa-miR-661, hsa-miR-2861, hsa-miR-23b-5p, hsa-miR-23a-5p, hsa-miR-4764-5p, hsa-miR-6734-3p, hsa-miR-4441, hsa-miR-4267, hsa-miR-4456, hsa-miR-7847-3p, hsa-miR-6515-5p, hsa-miR-5692b, hsa-miR-4664-5p, hsa-miR-342-5p, hsa-miR-5692c, hsa-miR-3911, hsa-miR-3960, hsa-miR-6852-5p, hsa-miR-4253, hsa-miR-6862-5p, hsa-miR-4296, hsa-miR-4695-5p, hsa-miR-4447, hsa-miR-4532 and hsa-miR-6752-3p) in humans which can target different regions in PDCD1gene. Multiple sequence alignments were also performed to investigate similarities among mature sequences of these miRNAs. Our data will provide concrete bases for the validation of thesemiRNAs.

Materials and methods

List of genes associated with TCR coinhibation identified in humans were collected from literature and publicly available databases. All the relevant publications were identified after searching PubMed with key words immunotolerence, graft transplant, cancer, materofetal or fetomaternal tolerance, Nivolumab etc. Out of all the genes obtained after keywords searching, PDCD1 was selected for this computational study as previously described study of Rahman et al. (2014).

The sequence of PDCD1 was retrieved from Genbank (NG_012110) . We used miRDB for searching of potential miRNA targets of PDCD1 gene. miRDB is an online computational tool for miRNA target prediction and functional annotations . The miRDB (MicroRNA target prediction and functional study data base http://mirdb.org/) was used for potential miRNA target identification in PDCD1 from NCBI Gene ID and predicts miRNA targets in for human.

Results and discussion

By using miRDB bioinformatic database, 26 potential miRNAs targeting PDCD1 gene in human were identified, given in Tables I as previously described study of Rahman et al. (2014) who predicted 11 targeting miRNA of GJB3 gene by using miRDB software. The miRDB is the computer based database for identification binding site in selected gene, which will provide strong further basis for experimental validation of these novel miRNAs in PDCD1. If validated by experiments, these miRNAs might be used as novel biomarkers for regulation of PDCD1 gene.

Tio et al. (2018) studied anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection. They came to know that among 6 patients with solid organ transplant shows graft rejection and including 1 death. Patients with HIV or hepatitis B/C respond well to anti-PD-1/PD-L1 immunotherapeutic treatment without any increased in toxicity.

Guleria and Sayegh (2007) studies that role of PD-1 upon binding with it ligand PD-L1 significantly increase rate of fetal survival due to shifting to Th2 cytokines, which are important for maintenance of successful pregnancy. Compared with the results of current study, PDCD1 may possibly responsible for programmed cell death.

Wang et al. (2017) reviewed that binding of PD1/PDL1 has been considered to play an important role in suppressing immune system which leads to invasion of tumor cells rejection of organ transplant and failure of fetomaternal tolerance. Thus, this study will provide the millstones for future researches to look on putative miRNA of PDCD1 gene.

The miR-661 has been well known to be involved in development of cancer in human beings . The hsa-miR-661 has helps the proliferation of the human cancerous cell line, this suggested that it may be a potential in therapy of lung cancer . miR-661 prevents the proliferation of human glioma cells, and their invasion and migration by targeting Telmerase reverse transcriptas TERT/hTERT) . Another previous study reported that miR-661 can promotes the ovarian cancer cells by directing targeting the inositol polyphosphate-5-phosphate J (INPP5j) gene .

Apoptosis, a form of program cell death has been studied in many degenerative diseases . The downregulation of miR-2861 may prevents the apoptosis of endometriotic tissue through the regulation of the MMp2 and STAT3. So, miR-2861 might be a potential therapeutic biomarker in endometriosis . The previous study identified the miR-2861 as a regulator of cardiomyocyte necrosis and suggest potential therapeutic biomarker in cardiac disease . miR-6734 arrested the cellular growth and causes

Table I.- miRNA targeting PDCD1 in human and list of 26 miRNA predicated by online tool miRDB in the sequence of Programmed cell death 1 (PDCD1) gene. Gene 5133 is predicted to be targeted by 26 miRNAs in miRDB.

S. No.

Precursor miRNA

Mature miRNA

Target Gene specifications

miR Base ID

Prec- ursor name

miR Base ID

mi RNA

Sequence

Len gth

Genomic location

Seed seq.

Seed loc.

1

MI000-5761

hsa-mir-939

MIMAT-0022939

hsa-miR-939

5' - CCCUGGGCC GCUCCCCAG - 3'

21

chr8:144394149-144394230 (-)

GCCC AGG

201, 627

2

MI000-3669

hsa-mir-661

MIMAT0-003324

hsa-miR-661

5' - UGCCUGGGU GCCUGCGCGU-3'

24

chr8:143945191-143945279 (-)

CCCA GGC

202, 628

3

MI001-3006

hsa-mir-2861

MIMAT-0013802

hsa-miR-2861

5' - GGGGCCUGG GUGGGCGG - 3'

19

chr9:127785918-127786007 (+)

CAGG CCC

642, 704, 820

4

MI000-0439

hsa-mir-23b

MIMAT-0004587

hsa-miR-23b-

5' - UGGGUUCCU UGCUGAUUU - 3'

22

chr9:95085208-95085304 (+)

GGAA CCC

913

5

MI000-0079

hsa-mir-23a

MIMAT-0004496

hsa-miR-23a-

5' - GGGGUUCCU GAUGGGAUUU-3'

22

hr19:13836587-13836659 (-)

GGA ACCC

913

6

MI001-7405

hsa-mir-4764

MIMAT-0019914

hsa-miR-4764

5' - UGGAUGUGG GAGUUAUCU - 3'

21

chr22:33436582-33436669 (-)

CA CA TCC

1029

7

MI002-2579

hsa-mir-6734

MIMAT-0027370

hsa-miR-6734

5' - CCCUUCCCU CUUCUCUCAG-3'

23

chr1:43364648-43364715 (-)

GGGA AGG

563, 971

8

MI00-16784

hsa-mir-4441

MIMAT-0018959

hsa-miR-4441

5' - ACAGGGAG GAUUGUA - 3'

17

chr2:239085827-239085926 (-)

CTCC CTG

292, 537

9

MI001-5871

hsa-mir-4267

MIMAT-0016893

hsa-miR-4267

5' - UCCAGCUC UGGCAC - 3'

16

chr2:110069961-110070042 (-)

GAG CTGG

689

10

MI001-6802

hsa-mir-4456

MIMAT-0018978

hsa-miR-4456

5' - CCUGGUGG UCCUUUU - 3'

17

chr5:535840-535882 (-)

CCAC CAG

14, 955, 1066

11

MI00-25517

hsa-mir-7847

MIMAT-0030422

hsa-miR-7847

5' - CGUGGAGGA GGAGGAGGC - 3'

21

chr11:1880045-1880147 (+)

CCTC CAC

33, 610

12

MI00-22227

hsa-mir-6515

MIMAT-0025486

hsa-miR-6515-

5' - UUGGAGGGU GAAGACAUC - 3'

21

chr19:12940484-12940540 (+)

CCC TCCA

32, 609

13

MI00-19311

hsa-mir-5692b

MIMAT-0022497

hsa-miR-5692

5' - AAUAAUAUC AGUAGGUGU - 3'

20

chr21:42950928-42951014 (-)

ATAT TAT

1139

14

MI00-17294

hsa-mir-4664

MIMAT-0019737

hsa-miR-4664

5' - UGGGGUGCC CGCAAGUU - 3'

22

chr8:143733083-143733153 (-)

GCAC CCC

1043

15

MI000-0805

hsa-mir-342

MIMAT-0004694

hsa-miR-342-

5' - AGGGGUGCU GUGAUUGA - 3'

21

chr14:100109655-100109753 (+)

GCAC CCC

1043

16

MI00-19288

hsa-mir-5692c-1

MIMAT-0022476

hsa-miR-5692

5' - AAUAAUAUC UAGGUGUAC - 3'

22

chr5:135802985-135803075 (-)

ATAT TAT

1139

17

MI00-16415

hsa-mir-3911

MIMAT-0018185

hsa-miR-3911

5' - UGUGUGGAU GGAGGAGGCA-3'

22

chr9:127690687-127690795 (-)

TCCA CAC

1033

18

MI00-16964

hsa-mir-3960

MIMAT-0019337

hsa-miR-3960

5' - GGCGGCGG GAGGCGGGG-3'

20

chr9:127785833-127785923 (+)

CCGC CGC

732

19

MI00-22698

hsa-mir-6852

MIMAT-0027604

hsa-miR-6852-

5' - CCCUGGGG GAGGACAUG -3'

21

chr9:35710676-35710741 (-)

CCCC AGG

521

20

MI00-15860

hsa-mir-4253

MIMAT-0016882

hsa-miR-4253

5' - AGGGCAUC CAGGGGGU - 3'

18

chr1:22863159-22863226 (-)

CATG CCC

624

21

MI002-2709

hsa-mir-6862-1

MIMAT-0027625

hsa-miR-6862-

5' - CGGGCAUG GGAGAGACU-3'

22

chr16:28390982-28391051 (-)

CATG CCC

624

22

MI00-15823

hsa-mir-4296

MIMAT-0016845

hsa-miR-4296

5' - AUGUGGG CAGGCUCA - 3'

17

chr10:125032783-125032870 (-)

GCCC ACA

190

23

MI001-7328

hsa-mir-4695

MIMAT-0019788

hsa-miR-4695

5' - CAGGAGGC GGCGAGCAG-3'

22

chr1:18883202-18883275 (-)

GCCT CCT

382, 724

24

MI00-16790

hsa-mir-4447

MIMAT-0018966

hsa-miR-4447

5' - GGUGGGGC UGUUGUUU - 3'

17

chr3:116850277-116850367 (-)

CCCC CAC

1046

25

MI001-6899

hsa-mir-4532

MIMAT-0019071

hsa-miR-4532

5' - CCCCGGG CCCGGCG - 3'

17

chr20:57895394-57895444 (+)

CCCC GGG

989

26

MI00-22597

hsa-mir-6752

MIMAT-0027405

hsa-miR-6752

5' - UCCCUGCA UACUCCCAG-3'

21

chr11:67490245-67490315 (+)

GGCA GGG

77, 594, 656, 801, 1059

the apoptosis of colon cancer cells by up-regulating the p-21 genes, which is suggesting the its key role in cancer cell survival and growth.

The miR-342 regulates the lumen formation of mammary gland morphogenesis . The Polymerase chain reaction (PCR) is a sensitive of molecular identification . Ding et al. (2016) has predicted that differentially expressed miRNAs in type 2 diabetes mellitus (T2DM) including hsa-miR-3960 by real time PCR. Their study might be helpful in subsequent experiments in T2DM.

Details of names of candidate miRNAs, their sequences, order of nucleotides, seed sequences and location target score and protein size of target gene has been shown in Table I, multiple sequence alignment, phylogenetic tree analysis of all the 26 miRNAs and purines and pyrimidines alignment of 26 miRNAs are shown in Supplementary Figure 1. All the miRNA targeting PDCD1 on miRDB were displayed in Tables I and Supplementary Figure 1.

Conclusion

The miRNAs are the novel class of small non-coding RNAs that targets in silencing of one or more genes. Keeping in view of importance of computer based prediction databases miRDB has been used in our study to mine the miRNAs targeting PDCD1 gene in human beings. We have identified 26 specific miRNAs in humans which can target different regions in PDCD1 gene. Our data will provide concrete bases for the validation of these miRNAs in silencing of PDCD1 gene.

Supplementary material

There is supplementary material associated with this article. Access the material online at: https://dx.doi.org/10.17582/journal.pjz/20191019021035

Statement of conflict of interest

Authors have declared no conflict of interest.

References

  1. Benson, D.A., Karsch-Mizrachi, I., Lipman, D.J., Ostell, J., Rapp, B.A. and Wheeler, D.L., 2000. Nucl. Acids Res., 28: 15-18.
  2. Cheng, X.S., Li, M.S., Du, J., Jiang, Q.Y., Wang, L., Yan, S.Y., Yu, D.M. and Deng, J.B., 2011. Anatom. Histol. Embryol., 40: 21-27. https://doi.org/10.1111/j.1439-0264.2010.01033.x[CrossRef]
  3. Chen, Y. and Wang, X., 2019. Nucl. Acids Res., 48: D127-D131. https://doi.org/10.1093/nar/gkz757[CrossRef]
  4. Chicurel, M., 2002. Nature, 419: 751-758.
  5. Ding, L., Ai, D., Wu, R., Zhang, T., Jing, L., Lu, J. and Zhong, L., 2016. Biosci. Biotechnol. Biochem., 80:461–465.
  6. Guleria, I. and Sayegh, M.H., 2007. J. Immunol., 178: 3345-3351.
  7. Jamieson, N.B., Morran, D.C., Morton, J.P., Ali, A., Dickson, E.J., Carter, C.R., Sansom, O.J., Evans, T.J., McKay, C.J. and Oien, K.A., 2012. Clin. Cancer Res., 18: 534-545. https://doi.org/10.1158/1078-0432.CCR-11-0679[CrossRef]
  8. Jiang, K., Guo, S., Zhang, T., Yang, Y., Zhao, G., Shaukat, A., Wu, H. and Deng, G., 2018. Front. Pharmacol., 9: 142. https://doi.org/10.3389/fphar.2018.00142[CrossRef]
  9. Li, Z., Liu, Y.H., Diao, H.Y., Ma, J. and Yao, Y.L., 2015. Biochem. biophys. Res. Commun., 468: 870-876. https://doi.org/10.1016/j.bbrc.2015.11.046[CrossRef]
  10. Lu, J., Gu, X., Liu, F., Rui, Z., Liu, M. and Zhao, L., 2019. Oncol. Rep., 41: 2987-2996.
  11. Rahman, K., Shah, A.A., Khan, M.H. and Ullah, S., 2014. Glob. J. Biotechnol. Biochem., 9: 41-49.
  12. Shaukat A., Khalid M., Irfan S., Tauseef u.R., Muhammad A.N., Ashar M., Muhammad I. S., Zia-ud-Din Sindhu, Shahid A.R., Mubashar H., Saqib U., Muhammad A.J., Rao Z.A. and Anas S.Q., 2019. Pakistan J. Zool., 51: 2023-2032.
  13. Syn, N.L., Teng, M.W., Mok, T.S. and Soo, R.A., 2017. Lancet Oncol., 18: e731-e741. https://doi.org/10.1016/S1470-2045(17)30607-1[CrossRef]
  14. Tio, M., Rai, R., Ezeoke, O.M., McQuade, J.L., Zimmer, L., Khoo, C., Park, J.J., Spain, L., Turajlic, S., Ardolino, L. and Yip, D., 2018. Eur. J. Cancer, 104: 137-144. https://doi.org/10.1016/j.ejca.2018.09.017[CrossRef]
  15. Wang, X., 2008. RNA, 14: 1012-1017.
  16. Wang, K., Long, B., Li, N., Li, L., Liu, C.Y., Dong, Y.H., Gao, J.N., Zhou, L.Y., Wang, C.Q. and Li, P.F., 2016. Free Rad. Biol. Med., 91: 58-67.
  17. Wang, Y., Li, Y., Wu, B., Shi, C. and Li, C., 2017. Mol. Med. Rep., 16: 2113-2120. https://doi.org/10.3892/mmr.2017.6827[CrossRef]
  18. Weng, C., Nguyen, T. and Shively, J.E., 2016. J. biol. Chem., 291: 16777-16786. https://doi.org/10.1074/jbc.M115.710152[CrossRef]
  19. Xia, Q., Wei, L., Zhang, Y., Sheng, J., Wu, W. and Zhang, Y., 2018. Mediators Inflammat., 2018: Article ID 1632902. https://doi.org/10.1155/2018/1632902[CrossRef]
  20. Yu, H., Zhong, Q., Xia, Y., Li, E., Wang, S. and Ren, R., 2019. Die Pharmazie-An Int. J. Pharmaceut. Sci., 74: 243-249.
  21. Zhang, T., Jiang, K., Zhu, X., Zhao, G., Wu, H., Deng, G. and Qiu, C., 2018. Int. J. biol. Sci., 14: 622. https://doi.org/10.7150/ijbs.24223[CrossRef]
  22. Zhu, T., Yuan, J., Wang, Y., Gong, C., Xie, Y. and Li, H., 2015. Biomed. Pharmacother., 75: 123-128.

Supplementary material

Services

Article usage statistics

Loading…

In Silico Profiling of Regulatory MicroRNA Targets in Programmed Cell Death 1 Gene · ResearchersLinks